|
|
TechnoVax’s intellectual property (IP) portfolio comprises issued U.S. and international patents licensed from Wyeth for all indications and fields of use plus pending patent applications filed by TechnoVax covering additional influenza vaccines such as 1918 flu, H7N7, H5N1 avian flu and further methods and compositions for multivalent VLP vaccines. These applications encompass the principal methods of virus-like particles (VLPs) formation and manufacturing, as well as the structural genes required for VLP assembly.
TechnoVax plans to file additional patent applications for new antigenic compositions of VLPs, as well as improved methods and compositions comprising VLPs having improved properties (e.g., enhanced intracellular formation and release, and increased immunogenicity.) Additionally, TechnoVax will develop a new biological method for VLP production that will translate into a more cost effective manufacturing system.
|
Presentación en Español